S1PR1 and myeloid sarcoma: A new therapeutic paradigm for the treatment of MS was introduced in 2010 and featured a modulation of the sphingosine 1-phosphate receptor 1 (S1P1) signaling by using fingolimod (FTY720, Gilenya®).